



HAL
open science

Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children

Doaa Elsherbiny, Yuan Ren, Helen Mcilleron, Gary Maartens, Ulrika S. H. Simonsson

► To cite this version:

Doaa Elsherbiny, Yuan Ren, Helen Mcilleron, Gary Maartens, Ulrika S. H. Simonsson. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. *European Journal of Clinical Pharmacology*, 2010, 66 (10), pp.1017-1023. 10.1007/s00228-010-0847-9 . hal-00600756

HAL Id: hal-00600756

<https://hal.science/hal-00600756>

Submitted on 16 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Population Pharmacokinetics of Lopinavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-Infected South African Children

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2009-0337.R1
Type of submission:	Original
Date Submitted by the Author:	09-Apr-2010
Complete List of Authors:	Simonsson, Ulrika; The Pharmacometrics Research Group, Department of Biopharmaceutical Sciences, Uppsala University McIlleron, Helen; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Ren, Yuan; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Elsherbiny, Doaa; The Pharmacometrics Research Group, Department of Biopharmaceutical Sciences, Uppsala University Maartens, Gary; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town

1
2
3 **Population Pharmacokinetics of Lopinavir in Combination with**
4
5
6 **Rifampicin-based Antitubercular Treatment in HIV-Infected South African**
7
8
9 **Children**

10
11
12
13
14 Doaa Elsherbiny¹, Yuan Ren², Helen McIlleron², Gary Maartens² and Ulrika S. H.
15
16 Simonsson^{1,*}
17

18
19
20
21 *¹Department of Pharmaceutical Biosciences, Uppsala University, Box 591, BMC, 751 24*
22
23 *Uppsala, Sweden*

24
25
26 *²Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape*
27
28 *Town, South Africa*
29

30
31
32
33 ***Corresponding Author:**

34
35 Dr Ulrika Simonsson

36
37 Department of Pharmaceutical Biosciences, Uppsala University, Box 591, SE-751 24

38
39 Uppsala, Sweden

40
41 Phone: +46 18 471 40 00

42
43 Fax: +46 18 471 40 03

44
45 Email: ulrika.simonsson@farmbio.uu.se

46
47 Running title: Lopinavir PK in children with rifampicin TB treatment

48
49
50
51
52
53
54
55
56
57
58
59
60
Keywords: lopinavir, ritonavir, pharmacokinetics, HIV, tuberculosis

Abstract

Objective The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/Human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin, were compared to the population PK of lopinavir in HIV infected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1).

Methods Lopinavir concentrations were measured in 15 TB/HIV co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate the induction of rifampicin. The children received median (inter quartile range= IQR) doses of lopinavir 292 mg/m² (274, 309) and ritonavir 301 mg/m² (286, 309) twice daily. After TB treatment completion the children received standard doses of lopinavir/ritonavir 4:1 (median [IQR] lopinavir dose 289 mg/m² [286, 303] twice daily) as were those without TB (median [IQR] lopinavir dose 265 mg/m² [249, 289] twice daily).

Results Lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C_{min} was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval.

Conclusions Increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.

Introduction

Human immunodeficiency virus (HIV) and tuberculosis (TB) co-infection is a major problem in sub-Saharan Africa. In South Africa, about 50% of children with TB aged between 0–12 years are HIV infected [1, 2]. Antiretroviral regimens including the lopinavir/ritonavir together with 2 nucleoside reverse transcriptase inhibitors (NRTIs) are commonly used in South African children. Lopinavir is a potent HIV protease inhibitor co-formulated with ritonavir in a ratio of 4:1. In this formulation, ritonavir acts as a booster of lopinavir concentrations due to its inhibitory effect on cytochrome P450 (CYP) enzyme 3A4 and P-glycoprotein which are involved in lopinavir metabolism and transport [3-5]. TB/HIV co-infected children should be treated with rifampicin for the whole TB treatment duration [9]. However, by inducing CYP3A4 and P-glycoprotein expression [6-8], rifampicin reduces protease inhibitor concentrations to subtherapeutic concentrations [9, 10]. In adults, rifampicin reduces the area under the-concentration-time curve (AUC) and minimum concentration (C_{min}) of lopinavir by 75% and 99%, respectively [11, 12]. Such reduction can be overcome, in healthy adults, by administering extra ritonavir (super-boosted lopinavir with lopinavir/ritonavir in a 1:1 ratio) since it results in lopinavir C_{min} similar to those obtained with a lopinavir/ritonavir (4:1) regimen without rifampicin [12]. This approach needs to be validated in children with TB/HIV co-infection since the expression of CYP enzymes and P-glycoprotein as well as protein binding may be altered by age or disease [13, 14]. The population pharmacokinetics of lopinavir in children has been published before by for example Jullien et al [15] and Rakhmanina et al [16] . However, these models do not describe or take into account the pharmacokinetic interaction between lopinavir and rifampicin. Neither is the population pharmacokinetics described when given together with the booster ritonavir. The latter has been described earlier [17, 18] but not in children. As tuberculosis and HIV are very commonly co-existing in children in developing countries, it is a great need

1
2
3 to develop population pharmacokinetic models in order to simulate and investigate optimal
4
5 doses and dosing recommendations.
6
7
8
9

10 The aim of this analysis was to develop a model describing the dynamic PK interactions and
11
12 comparing the population pharmacokinetics (PK) of lopinavir in TB/HIV co-infected South
13
14 African children taking lopinavir/ritonavir in the ratio of 1:1 in the presence of rifampicin
15
16 treatment, to the population PK of lopinavir in HIV infected South African children taking
17
18 lopinavir/ritonavir in the ratio of 4:1.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Study design

The data were available from a study consisting of two parallel treatment groups (Table 1), TB/HIV co-infected children and children with HIV but not TB [19]. The TB/HIV co-infected children comprised 15 children (8 females) who aged from 7 to 34 months, weighed between 5-13 kg and had body surface area (BSA) measurements between 0.28-0.54 m². The children received super-boosted lopinavir with a nominal lopinavir dose of 230 mg/m² (median [IQR] doses of lopinavir 292 mg/m² [274, 309] and ritonavir 301 mg/m² [286, 309] at the time of PK evaluation) twice daily in addition to 2 NRTIs, as well as rifampicin with a nominal dose of 10 mg/kg/day (median dose 9.4 mg/kg/day, dose range 6-12 mg/kg/day). Upon completing their TB treatment, the children received standard doses of lopinavir/ritonavir in the ratio of 4:1 with a nominal lopinavir dose of 230 mg/m² (median dose 289 mg/m² IQR 286, 303 mg/m² on the day PK was evaluated) twice daily in addition to 2 NRTIs. Ten of the 15 children returned for repeat PK sampling. The group without TB consisted of 15 children (10 females) aged from 9 to 47 months, and weighing between 5.6-16 kg with BSA measurements between 0.31-0.67 m². The children received lopinavir/ritonavir in the ratio of 4:1, with a nominal lopinavir dose of 230 mg/m² (median dose 265 mg/m², IQR 249, 289 mg/m² at PK evaluation) twice daily, in addition to 2 NRTIs. After a minimum of 4 weeks on the respective treatment regimens the children were admitted for blood sampling. Blood samples were taken just before an observed treatment dose and at 2, 3, 4, 5, 6, 8 and 12 hours after drug administration.

Data analysis

Lopinavir population PK were described using nonlinear mixed effects modelling within NONMEM version VI (GloboMax, Austin, Texas, U.S.A) [20]. The typical population pharmacokinetic parameters, interindividual variability (IIV) and residual variability were estimated by the first-order conditional estimation method with interaction.

One- and two-compartment models with first order absorption were fitted to the data.

Elimination was assumed to take place from the central compartment.

IIV was described using an exponential error model to avoid negative individual parameter estimates:

$$P_i = P \cdot \exp(\eta_i) \quad (1)$$

where P_i is the individual parameter, P is the typical parameter value and η_i is the IIV that describes the difference between the typical parameter value and the individual estimate. The variable η_i is normally distributed with mean 0 and variance ω^2 . Investigated residual error models were additive, proportional and slope-intercept models.

Model selection was achieved by the use of the objective function value (OFV) which is minus twice the log likelihood of the data. A drop in the OFV of 3.84 between two nested models corresponding to $p < 0.05$ was regarded as statistically significant. Graphical analysis using Xpose version 3.104 and version 4 [21], parameter estimates standard error, and scientific plausibility were used for model selection as well. Covariate model building was done by forward inclusion and backwards deletion using an OFV change of > 10.83 ($p < 0.001$) as the cut-off for inclusion, followed by stepwise deletion using an OFV change of > 12.12 ($p < 0.0001$) to retain the effect on the selected parameters.

1
2
3
4
5 Model validation was done by bootstrap resampling [22] and visual predictive check. In the
6
7
8 bootstrap resampling, parameter estimates were re-estimated for each of 1000 bootstrap
9
10 samples. NONMEM estimates from the final model were compared with the bootstrap median
11
12 and 95% confidence intervals. In the visual predictive check, the final model and parameter
13
14 estimates were used to simulate 1000 datasets based on the original design. Observed
15
16 concentrations were compared to the simulated median and 95% nonparametric prediction
17
18 interval.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Results

Lopinavir showed time-dependent oral clearance (CL/F) in all children. Lopinavir CL/F increased linearly during the dosing interval. Ritonavir inhibits CYP3A4 and hence the elimination of lopinavir [3]. Recovery from ritonavir inhibition during the dosing interval was described with a rate constant k_r . The final model for lopinavir oral clearance (CL/F) was:

$$(CL/F) = (CL/F)_0 \cdot (1 + [k_r \cdot TAD]) \quad (2)$$

where $(CL/F)_0$ is lopinavir CL/F at the beginning of the dosing interval and TAD is the time after dose in hours. The onset of recovery from enzyme inhibition was immediate since estimating a lag-time for the recovery did not lead to a drop in OFV. An exponential recovery from ritonavir inhibition did not offer any advantage over the linear recovery. Lopinavir $(CL/F)_0$ was 1.26, 1.17 and 0.90 L·h⁻¹ in co-infected children during TB treatment, after TB treatment and in the group without TB, respectively. Recovery from ritonavir inhibition of lopinavir metabolism was linear with a k_r of 0.0582 h⁻¹ during TB treatment, and 0.0648 h⁻¹ after TB treatment and in children without TB. This leads to a gradual increase in CL/F during the dosing interval reaching, at the end of the 12-hours dosing interval, 2.14, 2.08 and 1.59 L·h⁻¹ in the children during TB treatment, after TB treatment and in the group without TB, respectively. The data did not support having different k_r estimates for the co-infected group after TB treatment and the group without TB. Parameter estimates from the final pharmacokinetic lopinavir model are summarized in Table 2. None of the PK parameters were related to age, weight or gender.

The median sampling time (range) for the nominal 12-hour sample was 11.58 (10.50-12.07), 11.50 (9.25-12.00) and 12.00 (11.55-12.42) hours after dose administration in the children during and after TB treatment, and in those without TB, respectively. Due to the aforementioned wide ranges of the actual sampling time for the last sample, the nominal 12-

1
2
3 hour sample, lopinavir concentrations were predicted at 11.9 hours after dose administration.
4
5 Model predicted lopinavir concentrations, for all individuals, were above the recommended
6
7 minimum therapeutic concentration (1 mg/L) [23].
8
9

10
11
12 The bootstrap validation results showing the medians and the 95% confidence intervals for
13
14 1000 bootstrap samples are represented in Table 2. Figure 1 shows visual predictive check
15
16 plots obtained from simulation of 1000 datasets based on the final model. Figure 2 shows
17
18 plots of observed and individual predicted lopinavir concentration in children with poor,
19
20 typical and best goodness-of-fit, categorized by the average of the absolute weighted
21
22 individual residuals.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

1
2
3
4
5
6 Increasing the dose of ritonavir to achieve a lopinavir/ritonavir ratio of 1:1 was not able to
7
8 completely counteract the induction of lopinavir metabolism by rifampicin in this study as
9
10 lopinavir CL/F was modestly higher during TB treatment than it was after TB treatment
11
12 completion. Although giving larger doses of ritonavir may, in theory, fully compensate the
13
14 effect of rifampicin on lopinavir CL/F, this needs to be evaluated in patients. When ritonavir
15
16 was taken in therapeutic doses to act as HIV protease inhibitor, it induced CYP3A4 [24-26]
17
18 and, *in vitro*, ritonavir activates the pregnane X receptor though it decreases microsomal
19
20 CYP3A4 activity due to irreversible enzyme inhibition [27].
21
22
23
24
25
26

27 Even after TB treatment, CL/F in the co-infected children was greater than in children without
28
29 TB, indicating increased CL or reduced bioavailability of lopinavir, or both, in the TB/HIV
30
31 co-infected group. This could be attributed to a disease effect, or sampling bias as the study
32
33 was small. Lopinavir V/F was 2-fold larger in children with TB/HIV compared to children
34
35 without TB. Lopinavir is 98-99% bound to plasma proteins, mainly alpha-1-acid glycoprotein
36
37 and albumin [4]. The larger V/F in the co-infected children might be attributed to lower
38
39 albumin concentrations compared to children without TB [32, 35], or to reduced
40
41 bioavailability of lopinavir since the same trend was found in CL/F.
42
43
44
45
46
47
48

49 In healthy adults, administering extra ritonavir (lopinavir/ritonavir 1:1) resulted in similar
50
51 lopinavir maximum concentration and AUC as obtained with the standard lopinavir/ritonavir
52
53 (4:1) regimen without rifampicin [12]. The inability of the extra ritonavir dose to completely
54
55 counteract rifampicin induction of lopinavir CL/F in this study may be due to the higher
56
57 hepatic enzymatic activity in children between 1-4 years compared with adults [13]. However,
58
59 the clinically relevant criterion for monitoring virological efficacy is the trough sample at 12
60

1
2
3 hours after dose for drugs given twice daily [23]. The model predicted C_{\min} suggest that
4
5 administering extra ritonavir (lopinavir/ritonavir 1:1) is sufficient to maintain the C_{\min} above 1
6
7 mg/L in the studied children. However, this dosing regimen needs further evaluation in a
8
9 larger population of children. It is important to note that the BSA-derived doses of
10
11 lopinavir/ritonavir and ritonavir were rounded up to the nearest 0.5 mL of the oral solutions,
12
13 such that the doses/BSA of lopinavir and ritonavir, respectively, were 27% and 31% greater
14
15 than 230 mg/m² during TB treatment.
16
17
18

19
20
21 Lopinavir showed time-dependent PK where its CL/F increased linearly during the 12-hour
22
23 dosing interval probably due to recovery from inhibition by ritonavir. The recovery rate
24
25 constant, k_r , was 0.0582 h⁻¹ in the co-infected children during TB treatment, while after TB
26
27 treatment and in children without TB, k_r was and 0.0648 h⁻¹. The estimated k_r values
28
29 correspond to longer half-life values than those reported for ritonavir [29, 30] indicating that
30
31 enzymatic inhibition by ritonavir is mechanism-based and not only competitive. Assuming
32
33 mechanism-based inhibition and that the half-life of the inhibitor is negligible in comparison
34
35 to the turnover half-life of the enzyme, the rate constant for recovery from inhibition
36
37 corresponds to the rate constant of enzyme turnover [31]. The lower k_r during TB treatment,
38
39 in comparison to that after TB treatment and children without TB, may be due to the fact that
40
41 patients with TB/HIV co-infection have lower protein anabolism than patients with HIV
42
43 infection alone [32]. Recovery from ritonavir inhibition of CYP3A4 in adults is nearly
44
45 complete after 3 days of discontinuation [33]. Our estimated recovery half-life was 11.9 h
46
47 during TB treatment and 10.7 h after TB treatment and in the group without TB. This means
48
49 that after 3 days of discontinuation of ritonavir, the recovery in the co-infected children during
50
51 TB treatment would be 98% whilst after TB treatment and in the children without TB it would
52
53 be 99%. A previous attempt to link lopinavir population PK to ritonavir exposure resulted in a
54
55
56
57
58
59
60

1
2
3 time-independent inverse relationship between lopinavir CL/F and exposure to ritonavir [3].
4
5 However, since ritonavir plasma concentrations were not available from our study, there was
6
7 no relationship between lopinavir PK and ritonavir PK in the model.
8
9

10
11
12 Noncompartmental analysis of the data showed a non-significant trend for lopinavir half-life
13
14 ($t_{1/2}$) to be larger in the co-infected children during TB treatment compared to the children
15
16 without TB [19]. This is consistent with the estimated population pharmacokinetic parameters
17
18 since lopinavir $t_{1/2}$ at the beginning of the dosing interval and 12 hours after the dose,
19
20 respectively, were 11.5 h and 6.77 h for the co-infected children during TB treatment
21
22 compared to 7.98 h and 4.49 h in children without TB.
23
24
25
26
27
28

29
30 Our study may have been too small to detect any effects of age or sex within the 6-month to
31
32 4-year age range of the study. Very young children (≤ 6 -months) require increased doses/BSA
33
34 of lopinavir/ritonavir in order to achieve the same lopinavir concentrations as those in older
35
36 children and adults [28, 36, 31], and a 39% increase in CL/F has been reported for boys
37
38 compared to girls in children older than 12 years [37].
39
40
41
42

43
44 In conclusion, our study suggests that super-boosted lopinavir (lopinavir/ritonavir in the ratio
45
46 of 1:1) in children treated concomitantly with rifampicin-based TB treatment results in
47
48 therapeutic concentrations of lopinavir ($C_{\min} > 1$ mg/L). However, larger studies including
49
50 younger and older children are needed to evaluate the pharmacokinetics, safety and efficacy
51
52 of the combination of lopinavir, ritonavir and rifampicin in children. Lopinavir PK was time-
53
54 dependent probably due to recovery from ritonavir inhibition of lopinavir metabolism during
55
56 the dosing interval.
57
58
59
60

Acknowledgement

This study was supported by grants from the South African Department of Health (research programme for the comprehensive HIV and AIDS care, management and treatment plan for South Africa), the European and Developing Countries Clinical Trials Partnership (EDCTP), the Swedish International Development Cooperation Agency (SIDA) and the National Research Foundation South Africa (NRF).

For Peer Review

References

- [1] Jeena PM, Pillay P, Pillay T, Coovadia HM (2002) Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. *Int J Tuberc Lung Dis.* 6:672-678
- [2] Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R (2006) Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. *Clin Infect Dis.* 42:1040-1047
- [3] Lopinavir/Ritonavir (Kaletra) [package insert]. North Chicago (IL): Abbott Laboratories
- [4] Porche DJ (2001) Lopinavir/ritonavir. *J Assoc Nurses AIDS Care.* 12:101-104
- [5] Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. *Clinical Pharmacology and Therapeutics.* 81: 69-75
- [6] Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. *The Journal of Pharmacology and Experimental Therapeutics.* 299:849-857
- [7] Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. *Med Sci Monit.* 10:RA5-14
- [8] Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. *Clinical Pharmacokinetics.* 42:819-850
- [9] WHO (2006) Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. [cited October 2009]; Available from:

1
2
3 <http://www.who.int/child-adolescent->

4
5 [health/New_Publications/CHILD_HEALTH/WHO_FCH_CAH_2006.7.pdf](http://www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/WHO_FCH_CAH_2006.7.pdf)

6
7
8 [10] WHO (2006) ANTIRETROVIRAL THERAPY OF HIV INFECTION IN
9
10 INFANTS AND CHILDREN: TOWARDS UNIVERSAL ACCESS. Recommendations for a
11
12 public health approach. [cited October 2009]; Available from:

13
14 <http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf>

15
16 [11] CDC (2007) Table 2. Recommendations for coadministering protease inhibitors
17
18 and non-nucleoside reverse transcriptase inhibitors with RIFAMPIN [cited October 2009];
19
20 Available from: http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/Table2.htm

21
22 [12] La Porte CJ, Colbers EP, Bertz R, Voncken DS, Wikstrom KBoeree MJ,
23
24 Koopmans PP, Hekster YA, Burger DM (2004) Pharmacokinetics of adjusted-dose lopinavir-
25
26 ritonavir combined with rifampin in healthy volunteers. *Antimicrobial Agents and*
27
28 *Chemotherapy*. 48:1553-1560

29
30 [13] King JR, Kimberlin DW, Aldrovandi GM, Acosta EP (2002) Antiretroviral
31
32 pharmacokinetics in the paediatric population: a review. *Clinical Pharmacokinetics*. 41:1115-
33
34 1133

35
36 [14] Sankatsing SU, Beijnen JH, Schinkel AH, Lange JM, Prins JM (2004) P-
37
38 glycoprotein in human immunodeficiency virus type 1 infection and therapy. *Antimicrobial*
39
40 *Agents and Chemotherapy*. 48:1073-1081

41
42 [15] Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C,
43
44 Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Tréluyer JM. Population analysis of
45
46 weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children
47
48 from birth to 18 years. *Antimicrob Agents Chemother*. 2006 Nov;50(11):3548-3555

- 1
2
3 [16] Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely
4
5 MN. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations
6
7 in treatment-experienced human immunodeficiency virus-infected children. *Antimicrob*
8
9 *Agents Chemother.* 2009 Jun;53(6):2532-2538
10
11
12 [17] Moltó J, Barbanoj MJ, Miranda C, Blanco A, Santos JR, Negro E, Costa J,
13
14 Domingo P, Clotet B, Valle M. Simultaneous population pharmacokinetic model for
15
16 lopinavir and ritonavir in HIV-infected adults. *Clin Pharmacokinet.* 2008;47(10):681-692
17
18
19 [18] Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC,
20
21 Meenhorst PL, Huitema AD, Beijnen JH. Population pharmacokinetics of lopinavir in
22
23 combination with ritonavir in HIV-1-infected patients. *Br J Clin Pharmacol.* 2005
24
25
26
27
28
29
30
31 [19] Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G,
32
33 McIlleron HM (2008) Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-infected
34
35 Children with Tuberculosis *Journal of Acquired Immune Deficiency Syndromes.* 47:566-569
36
37
38 [20] Beal SL, Sheiner LS (1994) NONMEM user's guide, NONMEM Project Group,
39
40 University of California at San Francisco, San Francisco, USA
41
42
43 [21] Jonsson EN, Karlsson MO (1999) Xpose-an S-PLUS based population
44
45 pharmacokinetic/pharmacodynamic model building aid for NONMEM. *Comput Methods*
46
47 *Programs Biomed.* 58: 51-64
48
49
50 [22] Ette EI (1997) Stability and performance of a population pharmacokinetic
51
52 model. *Journal of Clinical Pharmacology.* 37:486-495
53
54
55 [23] Keulen (2006) Recommendations for performing TDM of antiretroviral agents.
56
57 [cited October 2009]; Available from:
58
59
60

1
2
3 <http://hivpharmacology.production.tdclighthouse.com/content.cfm?lang=1&id=573&id2=639>
4
5 &ch=4&cid=639

6
7
8 [24] Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG (1998) Neither dapsone
9 hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1
10 protease inhibitors. *European journal of clinical pharmacology*. 54: 741-747

11
12
13 [25] Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM,
14 Granneman GR (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in
15 healthy female volunteers. *British journal of clinical pharmacology*. 46:111-116

16
17
18 [26] Geletko SM, Erickson AD (2000) Decreased methadone effect after ritonavir
19 initiation. *Pharmacotherapy*. 20:93-94

20
21
22 [27] Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C,
23 Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson
24 A, Christ D, Selling B, LeCluyse E, Gan LS (2002) CYP3A4 induction by drugs: correlation
25 between a pregnane X receptor reporter gene assay and CYP3A4 expression in human
26 hepatocytes. *Drug metabolism and disposition: the biological fate of chemicals*. 30:795-804

27
28
29 [28] Verweel G, Burger DM, Sheehan NL, Bergshoeff AS, Warris A, van der Knaap
30 LC, Driessen G, de Groot R, Hartwig NG (2007) Plasma concentrations of the HIV-protease
31 inhibitor lopinavir are suboptimal in children aged 2 years and below. *Antiviral therapy*.
32 12:453-458

33
34
35 [29] Kappelhoff BS, Huitema AD, Crommentuyn KM, Mulder JW, Meenhorst PL,
36 van Gorp EC, Mairuhu AT, Beijnen JH (2005) Development and validation of a population
37 pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-
38 infected patients. *British journal of clinical pharmacology*. 59:174-182

39
40
41 [30] Ritonavir (Norvir) [product monograph]. Abbott Laboratories

- 1
2
3 [31] Venkatakrishnan K, Obach RS, Rostami-Hodjegan A (2007) Mechanism-based
4 inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug
5 interaction risk assessment. *Xenobiotica; the fate of foreign compounds in biological systems.*
6
7
8
9
10 37:1225-1256
11
- 12 [32] Paton NI, Ng YM, Chee CB, Persaud C, Jackson AA (2003) Effects of
13 tuberculosis and HIV infection on whole-body protein metabolism during feeding, measured
14 by the [15N]glycine method. *The American journal of clinical nutrition.* 78: 319-325
15
16
17
18
19
- 20 [33] Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS,
21 Court MH, Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on
22 cytochrome P450 3A activity in humans: comparison with ritonavir. *Clinical pharmacology*
23 and therapeutics. 79: 243-254
24
25
26
27
28
- 29 [34] Crommentuyn KM, Kappelhoff BS, Mulder JW, Mairuhu AT, van Gorp EC,
30 Meenhorst PL, Huitema AD, Beijnen JH (2005) Population pharmacokinetics of lopinavir in
31 combination with ritonavir in HIV-1-infected patients. *British journal of clinical*
32 pharmacology. 60: 378-389
33
34
35
36
37
38
- 39 [35] Paton NI, Ng YM (2006) Body composition studies in patients with wasting
40 associated with tuberculosis. *Nutrition Burbank, Los Angeles County, Calif. USA.* 22: 245-
41
42
43
44 251
45
- 46 [36] Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH,
47 Chen J, Palumbo P, Serchuck L, Smith E, Hughes M; P1030 team (2008) Pharmacokinetics,
48 safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
49
50
51
52
53
54
55
56
57
58
59
60
- 55 [37] Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C,
56 Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Tréluyer JM (2006) Population analysis

1
2
3 of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children
4
5 from birth to 18 years. *Antimicrobial agents and chemotherapy*. 50: 3548-3555

6
7
8 [38] Working Group on Antiretroviral Therapy and Medical Management of HIV-
9
10 Infected Children, François-Xavier Bagnoud Center, UMDNJ; The Health Resources and
11
12 Services Administration. The National Institutes of Health (2008) Guidelines for the Use of
13
14 Antiretroviral Agents in Pediatric HIV Infection. Available at:
15
16 <http://aidsinfo.nih.gov/OrderPublication/OrderPubsBrowseSearchResultsTable.aspx?MenuItem=AIDSinfoTools&ID=115>
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends*Figure 1*

Observed lopinavir concentrations (filled circles) versus time compared to simulated median (dashed line) and 5-95% prediction interval (dotted lines) based on 1000 simulations from the final model in (a) TB/HIV group during TB treatment, (b) TB/HIV group after TB treatment and (c) in HIV group.

Figure 2

Observed (open circles) and individual predicted (solid lines) lopinavir concentration-time curves from the final lopinavir pharmacokinetic model in (a) TB/HIV group during TB treatment, (b) TB/HIV group after TB treatment and (c) in HIV group (c). 'Poor', 'Typical' and 'Best' denote goodness-of-fit, categorized by the average of the absolute of weighted individual residuals.

Table 1 Study design

<i>TB/HIV group</i>	<i>HIV group</i>
<i>During TB treatment (n=15)*</i>	<i>n=15*</i>
lopinavir:ritonavir (1:1)	lopinavir:ritonavir (4:1)
230 mg/m ² x 2: 230 mg/m ² x 2	920 mg/m ² x 2: 230 mg/m ² x 2
2 NRTIs	2 NRTIs
Rifampicin 10 mg/kg/day	
<i>After TB treatment (n=10)*</i>	
lopinavir:ritonavir (4:1)	
920 mg/m ² x 2: 230 mg/m ² x 2	

*Blood sampling for PK determination was done after minimum 4 weeks of treatment

Table 2 Parameter estimates from the final pharmacokinetic lopinavir model

Parameter	Typical value		Interindividual variability	
	Estimate (RSE)	Bootstrap median (95% CI)	Estimate (RSE)	Bootstrap median (95% CI)
(CL/F) ₀ in TB/HIV group during TB treatment (L·h ⁻¹)	1.26 (0.11)	1.26 (1.06-1.5)	0.39 (0.24)	0.14 (0.081-0.21)
(CL/F) ₀ in TB/HIV group after TB treatment (L·h ⁻¹)	1.17 (0.14)	1.16 (0.933-1.48)	0.5 (0.29)	0.23 (0.11-0.36)
(CL/F) ₀ in HIV group (L·h ⁻¹)	0.895 (0.14)	0.904 (0.703-1.13)	0.5 (0.29)	0.23 (0.11-0.36)
k _r in TB/HIV group during TB treatment (h ⁻¹)	0.0582 (0.71)	0.06 (0.018-0.17)	1.9 (0.58)	3.1 (0.91-7.7)
k _r in TB/HIV group after TB treatment and in HIV group (h ⁻¹)	0.0648 (0.29)	0.064 (0.035-0.105)	0.7 (0.51)	0.48 (0.15-1.1)
V/F in TB/HIV group (L)†	20.9 (0.13)	20.5 (15.5-27.1)	0.86 (0.29)	0.74 (0.39-1.2)
V/F in HIV group (L)	10.3 (0.17)	10.0 (7.03-15.2)	0.44 (0.5)	0.17 (0.059-0.39)
k _a (h ⁻¹)	0.338 (0.076)	0.338 (0.244-0.403)	-	-
Proportional residual variability	0.155 (0.092)	0.154 (0.13-0.178)	-	-

TB= tuberculosis, HIV= Human immunodeficiency virus, RSE= relative standard error which is the ratio of the estimated standard error of the parameter relative to its value, CI= confidence interval, (CL/F)₀ = lopinavir oral clearance at the beginning of the dosing interval, k_r= rate constant for the dissipation of ritonavir enzyme inhibition, (CL/F)= oral clearance in a typical individual $(CL/F)_0 \cdot (1 + [k_r \cdot Time\ After\ Dose])$, V/F= volume of distribution, k_a= absorption rate constant

†Interindividual variability in V/F in TB/HIV group was only estimated during TB treatment.

Figure 1 a






Figure 1 b



Time (h)

review


Figure 1 c




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2 a

Poor fit



Typical fit



Best fit






Figure 2 b

Poor fit



Typical fit



Best fit






Figure 2 c

Poor fit



Typical fit



Best fit

